Paul Cottu, MD
Institut Curie Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Cottu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05296746 · Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerSOLTI Breast Cancer Research Group · active not recruiting · Breast Cancer Stage II · principal investigator
- Ph2NCT02400567 · Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenUNICANCER · completed · Neoadjuvant Operable Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.